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Abstract
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Myocardial toxicity and drug resistance caused by drug efflux are major limitations of doxorubicin
(Dox)-based chemotherapy. Dox structure modification could be used to develop conjugates with
an improved biological profile, such as antiproliferative activity and higher cellular retention.
Thus, Dox thiol conjugates, Dox thiol (Dox-SH), thiol-reactive Dox-SS-pyridine (SS = disulfide),
and a Dox-SS-cell-penetrating cyclic peptide, Dox-SS-[C(WR)4K], were synthesized. Dox was
reacted with Trauťs reagent to generate Dox-SH. The thiol group was activated by the reaction
with dithiodipyridine to afford the corresponding Dox-SS-Pyridine (Dox-SS-Pyr). A cyclic cell
penetrating peptide containing a cysteine residue [C(WR)4K] was prepared using Fmoc solid
phase strategy. Dox-SS-Py was reacted with the free sulfhydryl of cysteine in [C(WR)4K] to
generate Dox-SS-[C(WR)4K] as a Dox-cyclic peptide conjugate. Cytotoxicity of the compounds
was examined in human embryonic kidney (HEK-293), human ovarian cancer (SKOV-3), human
fibrosarcoma (HT-1080), and human leukemia (CCRF-CEM) cells. Dox-SH and Dox-SS-pyridine
were found to have significantly higher or comparable cytotoxicity when compared to Dox in
HEK-293, HT-1080, and CCRF-CEM cells after 24 h and 72 incubation, presumably because of
higher activity and retention of the compounds in these cells. Furthermore, Dox-SS-[C(WR)4K]
showed significantly higher cytotoxic activity in HEK-293, HT-1080, and SKOV-3 cells when
compared with Dox after 72 h incubation. Dox-SS-Pyr exhibited higher cellular uptake than
Dox-SS-[C(WR)4K] in HT-1080 and HEK-293 cells as shown by flow cytometry. Fluorescence
microscopy exhibited that Dox-SS-Pyr, Dox-SH, and Dox-SS-[C(WR)4K] localized in the
nucleus as shown in four cell lines, HT-1080, SKOV-3, MDA-MB-468, and MCF-7. Of note,
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Dox-SS-[C(WR)4K] was significantly less toxic in mouse myoblast cells compared to Dox at
the same concentration. Further mechanistic study demonstrated that the level of intracellular
reactive oxygen species (ROS) in myoblast cells exposed to Dox-SS-[C(WR)4K] was reduced
in comparison of Dox when co-treated with FeCl2. These data indicate that Dox-SH, Dox-SS
Pyr, and Dox-SS-[C(WR)4K] have the potential to be further examined as Dox alternatives and
anticancer agents.

Keywords
Anticancer; Cyclic peptide; Disulfide; Doxorubicin; Cellular uptake; Thiol; Cardiotoxicity

1.

Introduction

Author Manuscript

Cancer remains among the leading causes of morbidity and mortality around the world.
Approximately 17.5 million new cases and 8.7 million cancer-related deaths were reported
in 2015. During the next two decades, the number of new cases is estimated to rise by
70% [1]. Consequently, there is an urgent need to synthesize new potent and less toxic
chemotherapeutic agents.

Author Manuscript

One of the major limitations of cancer chemotherapy treatment is the development of tumor
resistance to the conventional chemotherapy. Tumors generally develop chemoresistance to
repeated treatment with one type of anticancer agent and then often become resistant to
similar or completely different drugs, which is called multidrug resistance (MDR). There are
two main classes of membrane transporter proteins which influence the pharmacokinetics
of drugs in cells, adenosine triphosphate-binding cassette (ABC) and solute carrier (SLC)
transporters, and their changes lead to MDR in tumors. In this regard, several hypotheses
have been proposed to account for the phenomenon of drug resistance, including alteration
of the target protein, decreased membrane permeability and drug metabolism, and/or efflux
pumping [2–4].

Author Manuscript

Doxorubicin (Dox) has been one of the most effective anthracycline antibiotics with a broad
anti-tumor spectrum since more than 50 years ago, as mono or in combination therapy
for the treatment of a variety of tumors, including solid tumors, soft tissue sarcomas, and
hematological malignancies [5–9]. Over the years, a variety of different mechanisms has
been proposed for the cytostatic and cytotoxic of Dox activity. However, the mechanism
of actions is uncertain and has long been the subject of considerable controversy [10]. The
main mechanism is the inhibition of topoisomerase II, critical to DNA function, causing
DNA damage by intercalation the DNA double helix [11,12]. Unfortunately, the use of Dox
has been limited clinically, due to its pharmacokinetics properties, such as rapid distribution,
excretion and low bioavailability, high volume of distribution, and short half-life [13–15].
Moreover, a high cumulative dose of Dox leads to dose-dependent side effects, such as
cumulative cardiotoxicity, nephrotoxicity, and extravasation [16–18]. Furthermore, Dox is
not used commonly for the treatment a number of tumors [19,20] due to efflux pumping,
such as ovarian carcinoma cells, leading to extrusion of Dox, keeping intracellular drug
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concentration below a cell-killing limit [21] that could be related to the overexpression of
energy-dependent drug efflux pump protein transporter, such as P-glycoprotein (P-gp).

Author Manuscript

Carrier-mediated drug delivery has emerged as a powerful methodology for optimizing
cellular uptake, improving the efficacy, and reducing the cytotoxicity of anticancer drugs
[22]. In this regard, drug delivery systems are viewed as one of the main pillars to overcome
MDR, through P-gp inhibition consequently, blocking efflux pump [23–26]. The prodrug
strategy, in which different substances can be attached to the molecule to modify its
chemical structure, has gained much attention in Dox delivery [27–29]. Several conjugation
methods have been used to improve Dox delivery including polymeric nanoparticles [30],
polymeric micelles [31], liposomes [32], lipids [33], dendrimers [34], and peptides [35–
37]. However, the release of the drug from the carrier is based primarily on reactions
catalyzed by endogenous physiological factors such as reduction [38], low pH [39], and
hydrolytic enzymes [40] and still presents a challenge. In this regard, researchers are
trying to incorporate Glutathione (GSH)-responsive moieties to impart stimuli-responsive
properties [41–43].
We have previously reported that cyclic peptides containing 4 arginine and 4 tryptophan
residues can act as a cell-penetrating peptide and molecular transporter [44–46]. Cyclic
[W(RW)4]-Dox conjugate containing an ester linker between the cyclic peptide-linker and
Dox exhibited 3.6-fold higher cellular uptake when compared with Dox alone in ovarian
cancer cells after 24 h incubation, and 99% of the conjugate was hydrolyzed to release Dox
intracellularly after 72 h [47].

Author Manuscript

The objective of this study was to generate Dox thiol derivatives for improving the Dox
biological profile, such as antiproliferative activity, cellular uptake, nuclear delivery, and
retention. Herein, a cell-penetrating cyclic peptide composed of arginine (R) and tryptophan
(W) was designed and conjugated with Dox via disulfide bridge to construct a smart drug
delivery system Dox-SS-[C(WR)4K]. The conjugate was evaluated for the antiproliferative
activity in different cancer cell lines, cellular uptake, and retention. We hypothesized that
Dox conjugation through the disulfide bridge with a cell-penetrating cyclic peptide would be
more efficient in antiproliferative activity against cancer cells that have a high concentration
of glutathione activity compared to the normal cells [48]. The disulfide bridge is expected to
be advantageous because they can be cleaved easily by disulfide exchange with intracellular
thiol such as glutathione. Furthermore, we also evaluated the antiproliferative activity
of Dox thiol derivatives, Dox-SH and Dox-SS-Pyridine (Dox-SS-Pyr), as potential Dox
alternatives in comparison with Dox-SS-[C(WR)4K] and Dox.

Author Manuscript

2.
2.1.

Results and discussion
Chemistry
2.1.1. Synthesis of cyclic peptide [C(WR)4K]—Cyclic peptide was composed of
positively-charged arginine (R) and hydrophobic tryptophan (W), in addition to β-Alanine
(A), lysine (K) and cysteine (C) residues and was synthesized by using a solid phase
methodology according to the previously reported procedure [49]. The thiol group in
cysteine moiety was used for the conjugation to the thiol-containing anticancer drug. The
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peptide sequence was designed to have lysine and β-Ala moieties as the spacer to provide a
free NH2 group with less steric hindrance.

Author Manuscript

As shown in Scheme 1, the linear protected peptide (Fmoc-R(Pbf =
2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl) C(Trt; trityl)R(Pbf)W(Boc = t
butoxycarbonyl)R(Pbf)W(Boc)K(β-A(Boc))W(Boc)R(Pbf)W(Boc)) was assembled on acid
labile chlorotrityl resin, followed by removing the last Fmoc (fluorenylmethyloxycarbonyl)
group on the N-terminal by piperidine (20% v/v, DMF). The peptidyl-resin was washed,
dried, and the resin was removed by a mild acidic cocktail cleavage (DCM/TFE/AcOH) [50]
to afford the linear protected peptide with free amino and carboxylic groups. The peptide
was cyclized using 1-hydroxy-7-azabenzotriazole (HOAt) and N,N'-diisopropylcarbodiimide
(DIC) as coupling reagents under anhydrous conditions, followed by side chain deprotection
to generate the targeted peptide[C(WR)4K]. The structure of the cyclic peptide was
confirmed by MALDI-TOF/TOF mass spectrometry, showing a peak of 1675.4534 Da
(Supporting Information), corresponding to [M+5H]+.
2.1.2. Synthesis of Dox-SH, Dox-SS-Pyr—Moreover, Dox was modified by reacting
with a bifunctional cross linking agent. The amine group of Dox was reacted with 2
iminothiolane hydrochloride (Trauťs reagent) under optimal conditions of basic medium to
generate Dox-SH, containing an amidine with a free sulfhydryl group, which was activated
by reacting with pyridyl disulfide (Pyr-SS-Pyr) (SS = disulfide) in acidic medium, affording
the corresponding more reactive Dox-SS-Pyr containing a disulfide bridge with extrusion
of pyridine-2-thione as depicted in Scheme 2. This type of chemical modification for Dox
permitted the conjugation with the thiol group in the cysteine - of the cyclic peptide.

Author Manuscript

2.1.3. Synthesis of Dox-SS-[C(WR)4K]—Cyclic peptide [C(WR)4K] was conjugated
with Dox-activated disulfide (Dox-SS-Pyr) via thiolate-disulfide interchange, using water
as a polar protic solvent (Scheme 3). Mass spectra showed 2315.3719 Da corresponding
to [M+2H]+, in addition to 1919.0574 (extrusion tetracyclic anthracycline aglycone) and
1672.0049 (the cysteinyl peptide) as fragments (Supporting Information, 1D) since disulfide
peptide can be specifically fragmented at S-S bond during MALDI-MS as shown previously
for other disulfide compounds [51]. The Dox-SS-[C(WR)4K] product was purified by
reverse-phase preparative HPLC (RP-HPLC) on a C18 column and lyophilized. The purity
of the product was determined by analytical HPLC (Supporting Information, 3D).
2.2.

Biological activities

Author Manuscript

Dox is commonly used in the treatment of leukemia, multiple lymphoma, thyroid, ovarian,
lung, and breast cancers. Thus, antiproliferative activity of Dox-SH, Dox-SS-Pyr, and the
conjugate were compared with Dox at a concentration of 5 μM in human leukemia cell line
(CCRF-CEM, ATCC No. CCL-119) [6], human ovarian cancer cells (SKOV-3, ATCC No.
HTB-77), human fibrosarcoma cells (HT-1080, ATCC No. CRL 12012) [7,52], and human
embryonic kidney cells (HEK-293, ATCC No. CRL-1573) [53,54] (Figs. 1 and 2). We
chose different cancer cell lines (e.g. CCRF-CEM, SKOV-3, HT-1080) and normal human
embryonic kidney cells (HEK-293) to test both cytotoxicity and antiproliferative activity of
synthesized compounds versus Dox.
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Fig. 1 shows the antiproliferative activity of Dox versus Dox-SS-Pyr and Dox-SH. Dox-SS
Pyr inhibited the cell proliferation of HEK-293 (66%), HT-1080 (80%), and SKOV-3 (72%),
and CCRF-CEM cells (46%) after 24 h incubation while Dox alone exhibited inhibition
the cell proliferation of HEK-293 (57%), HT-1080 (66%), and SKOV-3 (76%), and CCRF
CEM cells (45%). Thus, Dox-SS-Pyr showed significantly higher cytotoxicity than Dox in
HEK-293 and HT-1080 when compared with Dox while showed comparable activity against
and SKOV-3 cells CCRF-CEM cells after 24 h incubation.

Author Manuscript

After 72 h incubation, Dox-SS-Pyr inhibited the cell proliferation of HEK-293 (60%),
HT-1080 (68%), and SKOV-3 (39%), and CCRF-CEM cells (73%). Dox alone did not
exhibit inhibition the cell proliferation of HEK-293 and HT-1080, while inhibited the
proliferation of SKOV-3 (51%) and CCRF-CEM cells (69%). Thus, Dox-SS-Pyr was more
cytotoxic than Dox in all cell lines except SKOV-3 after 72 h incubation when compared
with Dox. The antiproliferative activities of the compounds in HEK-293, HT-1080, and
SKOV-3 were found to be less after 72 h, possibly due to the efflux mechanism. However,
this effect was more obvious in HEK-293 and HT-1080 where Dox did not show any
significant cytotoxicity. Thus, Dox-SS-Pyr enhances the intracellular retention of Dox in
HEK-293 and HT-1080 cells while Dox had no effect.

Author Manuscript

Dox-SH inhibited the cell proliferation of HEK-293 (61% and 64%), HT-1080 (62% and
68%), and SKOV-3 (64% and 42%), and CCRF-CEM cells (48% and 73%) after 24 h and
72 h incubation, respectively, suggesting slightly higher inhibition and retention in all cells
in longer incubation time except SKOV-3 cells. Furthermore, Dox-SH was found to be more
cytotoxic in all cell lines except SKOV-3 cells when compared with Dox alone after 24 h
and 72 h incubation. Dox-SH was less cytotoxic in HEK-293, HT-1080, and SKOV-3 cells
when compared with Dox-SS-Pyr after 24 h incubation, but showed comparable activity
after 72 h incubation. These data indicate Dox-SH and Dox-SS-Pyr have significantly higher
or comparable antiproliferative activity when compared to Dox in HEK-293, HT-1080, and
CCRF-CEM cells after 24 h and 72 incubation, presumably because of higher activity and
retention of the compounds in these cells. We speculate Dox-SS-Pyr hydrolyzes and releases
Dox-SH slowly in the presence of intracellular thiol groups, such as glutathione. Hence,
Dox-SH and Dox-SS-Pyr have comparable activity after 72 h.

Author Manuscript

Fig. 2 shows the antiproliferative activity of the cyclic peptide [C(WR)4K], Dox-SS
[C(WR)4K], and the physical mixture of Dox and [C(WR)4K] versus Dox. In general,
cyclic peptide [C(WR)4K] alone did not exhibit any significant cytotoxicity against HT-1080
and CCRF-CEM cells after 24 h incubation and against HEK-293 and CCRF-CEM cells
after 72 h incubation. The compound inhibited the proliferation of HEK-293 (12%) and
SKOV-3 cells (13%) after 24 h incubation and HT-1080 (12%) and SKOV-3 (6%) after
72 h incubation. Thus, the contribution of the cyclic peptide in overall cytotoxicity in
the conjugate is minimal. While Dox-SS-[C(WR)4K] exhibited slightly higher inhibition
of proliferation in SKOV-3 cells when compared with Dox (71% versus 66%) after 24 h
incubation, comparable cytotoxicity was observed when two compounds were compared in
HEK-293, HT-1080, and CCRF-CEM cells. The physical mixture of Dox and [C(WR)4K]
also exhibited comparable cytotoxicity with Dox in all cell lines after 24 h incubation.
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On the other hand, Dox-SS-[C(WR)4K] inhibited the proliferation of HEK-293 (32%),
HT-1080 (49%), SKOV-3 (58%), and CCRF-CEM cells (68%) after 72 h incubation while
Dox alone did not inhibit the cell proliferation of HEK-293 and HT-1080 cells and exhibited
antiproliferative activity in SKOV-3 (51%) and CCRF-CEM cells (69%). Thus, Dox-SS
[C(WR)4K] showed comparatively higher cytotoxicity in HEK-293, HT-1080, and SKOV-3
cells when compared with Dox after 72 h incubation, suggesting that the conjugate enhanced
the retention of Dox in these cells presumably by slowly releasing Dox and reducing the
efflux.

Author Manuscript

The physical mixture of Dox and [C(WR)4K] was found to show no inhibition in HEK-293
and HT-1080 cells after 72 h incubation similar to Dox but showed comparable activity
with Dox in SKOV-3 and CCRF-CEM cells. These data indicate that the physical mixture
has no advantage compared to Dox, and the cytotoxicity of the physical mixture is due to
the presence of free Dox. Furthermore, the cyclic peptide does not improve the delivery or
retention of Dox when used in the physical mixture form with Dox. On the other hand,
Dox-SS-[C(WR)4K] is more cytotoxic than Dox in HEK-293, HT-1080, and SKOV-3 cells
after 72 h incubation, suggesting the potential of the conjugate to improve the cytotoxicity
and retention of Dox.

Author Manuscript

Comparison of Dox-SS-[C(WR)4K] with Dox-SS-Pyr (Figs. 1 and 2) revealed that the
conjugate was significantly less cytotoxic than Dox-SS-Pyr in HEK-293 (54% versus 66%),
HT-1080 (51% versus 80%) and showed comparable activity against SKOV-3 (71% versus
72%), and CCRF-CEM (42% versus 46%), respectively, after 24 h incubation. Similarly the
Dox-SS-[C(WR)4K] was less cytotoxic than Dox-SS-Pyr in HEK-293 (32% versus 60%),
HT-1080 (49% versus 68%), and CCRF-CEM (68% versus 73%) cells after 72 h incubation,
but was more cytotoxic against SKOV-3 (58% versus 39%), respectively. These data suggest
that Dox-SS-Pyr has higher antiproliferative activity than the conjugate in all cell lines after
24 h incubation and in HEK-293, HT-1080, and CCRF-CEM cells after 72 h incubation.
Flow cytometry was used to determine the cellular uptake of the conjugate Dox-SS
[C(WR)4K] versus Dox-SS-Pyr in HEK-293, HT-1080, SKOV-3, and CCRF-CEM cells
(Fig. 3). Cellular uptake studies indicated that Dox-SS-Pyr had higher cellular uptake in
HT-1080, HEK-293, and CCRF-CEM cells when compared with Dox-SS-[C(WR)4K]. Dox
and Dox-SS-[C(WR)4K] showed a similar pattern and had higher cellular uptake in SKOV-3
and HT-1080 cells.

Author Manuscript

Based on the cytotoxicity and flow cytometry data Dox-SH, Dox-SS-Pyr, and Dox-SS
[C(WR)4K] were selected for fluorescence microscopy studies. Fluorescence microscopy
was used to evaluate the cellular uptake and cellular localization in HT-1080, SKOV-3,
human breast adenocarcinoma (MDA-MB-468, ATCC No. HTB-132), and human breast
adenocarcinoma cell (MCF-7, ATCC No. HTB-22). Figs. 4 and 5, and S1 show localization
of all the compounds after 1 h and 24 h in the nucleus in HT-1080, MDA-MB-468, and
MCF-7 cells. Dox-SH and Dox-SS-Pyr exhibited much higher intensity when compared
with Dox as shown in Figs. 4 and 5, and Figures S1 and S2 (Supporting Information).
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Dox-SS-[C(WR)4K] and Dox was localized in the nucleus after 1 h and 24 h in SKOV-3
cells while Dox-SH and Dox-SS-Pyr were distributed mostly outside the nucleus after 1 h.
After 24 h, all the compounds were mostly localized in the nucleus (Figure S2), suggesting
the slow nuclear localization of Dox-SH and Dox-SS-Pyr in SKOV-3 cells. These data
indicate that Dox-SH, Dox-SS-Pyr and Dox-SS-[C(WR)4K] can be localized in the nucleus
that allows DNA targeting by potentially released Dox or the intact compound.
2.3.

Cytotoxicity in mouse myoblast cells

Author Manuscript

The clinical use of Dox is greatly limited by the risk of developing severe cardiomyopathy
and congestive heart failure. In order to investigate the potential cardiotoxicity of Dox
SS-[C(WR)4K] in comparison to Dox, a mouse myoblast cell line (C2C12, ATCC No.
CRL 1772) was used in the study. Cells were maintained in DMEM (ATCC No. 30–
2002) containing 10% fetal bovine serum at 37 °C. After incubation with Dox or Dox
SS-[C(WR)4K] for 72 h, cell viability was determined by MTT colorimetric analysis as
described before [55].
As shown in Fig. 6, at m5M concentration, Dox treatment significantly reduced the cell
viability to 28.6% of control, while in cells exposed to Dox-SS-[C(WR)4K], the cell
survival rate was significantly increased (71% of control, p < 0.05 compared to Dox alone),
indicating that Dox-SS-[C(WR)4K] may exhibit less cardiotoxicity in comparison to Dox.

Author Manuscript

Oxidative stress has been well documented as the primary cause of anthracycline
induced cardiotoxicity (AIC) [56], which is exacerbated by iron overload [56,57]. To
further determine the effect of Dox-SS-[C(WR)4K] on reactive oxygen spices (ROS),
we conducted flow cytometry analysis using a cell-permeant fluorogenic reagent 2',7'
dichlorodihydrofluorescein diacetate (H2DCFDA) (ThermoFisher Scientific, Cat. No.
D399), which can detect intracellular reactive oxygen intermediates.
Cultured C2C12 cells in a 6 well plate were treated with Fe2+ (10 μM) in the absence or
presence of Dox or Dox-SS-[C(WR)4K] (0.5 μM) for 72 h. Once the incubation period was
complete, cells were collected and stained with H2DCFDA (10 μM) to detect intracellular
ROS levels [55].
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As shown in Fig. 7, FeCl2 treatment increased the intracellular ROS levels to 2.5-fold of
control, while the levels of ROS in cells exposed to Dox or Dox-SS-[C(WR)4K] alone at low
concentration (0.5 mM) were not elevated in comparison to that of control cells (1.09-fold
and 1.05-fold of control respectively). Notably, the coincubation of Dox with Fe2+ increased
ROS levels higher to 3.48-folds of control; however, induction in Fe2+-treated cells was not
observed in the presence of Dox-SS-[C(WR)4K]. The distinct pattern of effects on ROS
generation between Dox and Dox-SS-[C(WR)4K] may explain, at least partially, the reduced
cytotoxicity of Dox-SS-[C(WR)4K] in C2C12 cells. Further study is warranted to define the
underlying mechanisms.
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Dox thiol conjugates, thiolated doxorubicin (Dox-SH), thiol-reactive Dox-SS-Pyr, and a
Dox-SS-cell-penetrating cyclic peptide, Dox-SS-[C(WR)4K] were synthesized and purified
by using RP-HPLC. Dox-SS-Pyr showed significantly higher antiproliferative activity than
Dox in HEK-293, HT-1080, and SKOV-3 cells when compared with Dox which showed
comparable activity against CCRF-CEM cells after 24 h incubation. Dox-SS-[C(WR)4K]
was found to be more cytotoxic in HEK-293, HT-1080, and SKOV-3 cells when compared
with Dox after 72 h incubation. Dox-SS-Pyr exhibited higher cellular uptake in HT-1080,
HEK-293, and CCRF-CEM cells as shown by flow cytometry when compared with Dox-SS
[C(WR)4K]. Dox-SS-Pyr, Dox-SH, and Dox-SS-[C(WR)4K] showed high cellular uptake
and were localized mostly in the nucleus as shown consistently in four different cancer
cell lines by fluorescence microscopy studies. Our study further demonstrated that Dox-SS
[C(WR)4K] exhibited less cytotoxicity in mouse myoblast cells in comparison to Dox.
Intracellular ROS levels were elevated by the co-treatment of Dox and Fe2+, but such
induction was not evident in cells exposed to Dox-SS-[C(WR)4K] and Fe2+. These data
indicate that these compounds can be considered as Dox alternatives and anticancer agents,
which may exhibit less cardiotoxicity in comparison to Dox.

4.
4.1.

Experimental section
Materials and methods

Author Manuscript

The resin, Fmoc-protected amino acid building blocks, and chemical reagents were
purchased from AAPPTec. All solvents used for peptide synthesis or HPLC solvents
were obtained from Sigma-Aldrich, USA and used without further purification. Peptide
purification was carried out using Shimadzu RP-HPLC system, C18 column (19 cm × 250
mm), and the purity was confirmed by analytical HPLC, using water (0.1% TFA) as eluent
A and acetonitrile (0.1% TFA) as eluent B. NMR spectra were recorded on a Bruker Avance
III HDTM 400 NMR spectrometer using DMSO-d6 as the solvent and TMS as internal
reference. Mass spectra were obtained by a Bruker Impact 11, UHR-qTOF and a Bruker
Daltonics Autoflex MALDI-TOF, with α-cyano-4-hydroxycinnamic Acid (CHCA) as the
matrix (15 mg/mL).
4.2.

Chemistry

Author Manuscript

4.2.1. Synthesis cyclic peptide [C(WR)4K]—Cyclic peptide [C(WR)4K]
was synthesized by Fmoc/tBu solid-phase peptide synthesis strategy. The
coupling and activating reagents were N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uro
niumhexafluorophosphate (HBTU) and N,N-diisopropylethylamine (DIPEA), respectively,
in anhydrous N,N-dimethylformamide (DMF). Fmoc was deprotected using piperidine in
DMF (20% v/v). The H-Trp(Boc)-2-chlorotrityl resin (811 mg, 0.30 mmol, 0.37 mmol/g)
was swelled in DMF (10 mL) for 10 min with shaking and mixing using N2. The excess
of DMF was filtered off. The swelling and filtration steps were repeated two times before
the coupling reactions. The solvent was drained, followed by coupling with Fmoc-Arg(Pbf)
OH (583 mg, 0.90 mmol, 3 equiv.) using HBTU (341 mg, 0.90 mmol, 3 equiv.) and
DIPEA (313 μL, 1.80 mmol, 6 equiv.) in anhydrous DMF (5 mL) for 1 h. The resin was

Eur J Med Chem. Author manuscript; available in PMC 2021 September 05.

Darwish et al.

Page 9

Author Manuscript
Author Manuscript

washed three times using DMF (3 × 10 mL), followed by deprotection of Fmoc group by
previously prepared piperidine solution in DMF (20 mL, 20% v/v). The resin was washed
with DMF three times (3 × 10 mL) to be ready for the next coupling. The subsequent
amino acids, Fmoc-Trp(Boc)-OH (473 mg, 0.90 mmol, 3 equiv.), Dde-Lys(Fmoc)-OH (479
mg, 0.90 mmol, 3 equiv.), Fmoc-Trp(Boc)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Trp(Boc)-OH,
Fmoc-Arg(Pbf)-OH, Fmoc-Cys(Trt)-OH (527 mg, 0.90 mmol) and Fmoc-Arg(Pbf)-OH were
coupled in the same manner. The Dde (1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl)
group of Dde-Lys (Fmoc)-OH was removed using hydrazine hydrate in DMF (2% v/v, 20
mL, 2 × 5 min) before coupling with Boc-β-Ala-OH (170 mg, 0.90 mmol, 3 equiv.). The
deprotection of Fmoc groups was achieved with the piperidine solution. The side-chain
protected peptide was cleaved from the resin by shaking the resin with a mixture of
dichloromethane (DCM)/2,2,2-trifluoroethanol (TFE)/acetic acid (AcOH) (50 mL, 7:2:1,
v/v/v) for 1 h. The resin was filtered off, and the solution was evaporated under vacuum,
using hexane to remove acetic acid azeotropically. The residue was dried overnight under
vacuum. The crude linear protected peptide was used directly for cyclization. The crude
peptide was dissolved in a diluted solution of DMF/DCM (240 mL, 4:1 v/v) under inert gas,
using HOAt (122 mg, 0.90 mmol) and DIC (139 μl, 0.90 mmol) as coupling reagents.
The mixture was stirred overnight at rt. After cyclization, the solvent was evaporated
and cleavage of the side-chain protecting groups was carried out by using trifluoroacetic
acid (TFA)/thioanisole/1,2-ethanedithiol (EDT)/anisole (90:5:3:2, v/v/v/v, 10 mL) for 2 h.
The crude deprotected cyclic peptide was precipitated with addition of cold diethyl ether
treatment followed by centrifugation, providing the targeted cyclic peptide, which was
purified by using RP-HPLC (reversed-phase high-performance liquid chromatography). The
fraction was evaporated and lyophilized to afford the powdered cyclic peptide. MALDI-TOF
(m/z) [C80H110N28O11S]: calcd, 1670.8630; found, 1675.4534 [M + 5H]+.
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4.2.2. Synthesis thiolated doxorubicin (Dox-SH)—Dox (50 mg, 0.09 mmol) and
2-iminothiolane hydrochloride (12 mg, 0.09 mmol) were dissolved in methanol (40 mL)
followed by addition of a catalytic amount of triethylamine (TEA) and stirred at rt for 7 h.
After evaporation of the solution, the crude product was washed multiple times with diethyl
ether affording 45 mg (70%) of Dox-SH. 1H NMR (DMSO-d6 + D2O, 400 MHz, δ ppm):
7.90–7.83 (m, 2H, ArC1H, ArC2H), 7.62–7.60 (m, 1H, ArC3H), 5.26 (t, J = 12.0 Hz, 1H,
H-1'), 4.95–4.86 (m, 1H, H-14), 4.50–4.59 (m, 3H, H-14 and H-7), 4.15 (d, J = 8.0 Hz,
1H, H-50), 3.95 (d, J = 12.0 Hz, 3H, OCH3), 3.55–3.50 (m, 1H, H-4'), 3.39–3.30 (m, 1H,
H-3'), 2.80–2.96 (m, 2H, H-10), 244–2.32 (m, 2H, CH2SH), 2.17–1.42 (m, 8H, CH2 (H-8),
HSCH2CH2, CH2C=NH, CH2 (H-2'), 1.16–1.10 (br S, 3H, CH3); 13CNMR (DMSO-d6 +
D2O, 100 MHz, δ ppm): 214.39 (C13 = O), 187.07 (C12 = O),186.52 (C5=O), 166.53
(C-4), 161.33 (C=NH), 156.16 (C-6), 154..62 (C-11), 137.13 (C-6a), 135.40 (C-10a), 135.06
(C-12a), 134.51 (C-2), 120.33 (C-4a), 120.23 (C-1), 119.76 (C-3), 111.30 (C-5a), 110.93
(C-11a), 99.81 (C-1'), 75.73 (C-9), 75.37 (C-7), 70.35 (C-4'), 66.75 (C-5'), 64.25 (C-14),
57.16 (C4-OCH3), 47.06 (C3'), 36.77 (C-8), 32.57 (C-10), 32.46 (C-2'), 28.56 (CH2C(NH)
= NH), 27.53 (CH2SH), 26.82 (CH2CH2SH), 17.21 (C-5'-CH3); HR-MS (ESI-qTOF) (m/z)
[C31H36N2O11S]: calcd, 644.2040; found 645.4678 [M+H]+.
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4.2.3. Synthesis of pyridyl doxorubicin (Dox-SS-Pyr)—Thiolated Dox (100 mg,
0.15 mmol) and 2,2'-dithiodipyridine (33 mg, 0.15 mmol) were dissolved in methanol
(40 mL) followed by adding a catalytic amount of acetic acid (AcOH). The mixture was
stirred overnight at room temperature. After evaporation of the solution, the precipitated
product was crystallized from diethyl ether, affording 85 mg (73%) of Dox-SS-Pyr. 1H NMR
(DMSO-d6, 400 MHz, δ ppm): 14.08 (s, 1H, OH Phenolic C-6), 13.28 (s, 1H, OH Phenolic
C-11), 8.47–7.28 (m, 9H, NH and ArH), 5.37–5.31 (m, 2H, CH2OH), 5.04–5.01 (m, 2H,
OH Sugar and OH cyclohexane), 4.61–4.55 (m, 1H, OH, CH2OH), 3.98 (s, 3H, OCH3),
1.61–1.57 (m, 17H, CH2 and CH of sugar, cyclohexane and thiolane), 1.14 (d, J = 6.8
Hz, 3H, CH3); 13C NMR (DMSO-d6, 100 MHz, δ ppm): 207.80 (C13 = O),186.90 (C12 =
O), 185.70 (C5=O), 165.09 (C-4), 161.09 (C=NH), 158.90, 157.33, 154.39, 149.72, 149.61,
138.17, 137.82, 136.38, 134.20, 121.82, 121.21, 119.55, 119.28, 112.83, 110.63, 110.43 (16
Aromatic carbons), 99.26, 74.87, 68.93, 64.30, 63.06, 48.66, 38.88, 36.60, 32.56, 31.29,
28.20, 26.43 (12C, CH2 and CH of sugar, cyclohexane and thiolane), 63.06 (CH2OH), 56.60
(OCH3), 16.89 (CH3); HR-MS (ESI-qTOF) (m/z) [C36H39N3O11S2]: calcd, 753.2026; found
754.4053 [M+H]+.
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4.2.4. Synthesis of cyclic peptide attached doxorubicin (Dox-SS[C(WR)4K])—
A cyclic peptide ([C(WR)4K], 30 mg, 0.01 mmol) and the activated Dox (Dox-SS-Pyr, 11
mg, 0.01 mmol) were dissolved in methanol/water mixture (1:4, v/v, 4 mL). The reaction
mixture was stirred under nitrogen overnight at rt. After completion of the reaction as
monitored by MALDI mass, the solution was concentrated using rotatory evaporator and
subjected to RP-HPLC for purification, followed by analytical HPLC to confirm the purity.
MALDI-TOF (m/z) [C111H144N30O22S2]: calcd, 2313.0513; found 2315.3719 [M + 2H]+.
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4.3.

Cell culture
Human embryonic kidney cells (HEK-293, ATCC No. CRL-1573), human ovarian cancer
cells (SKOV-3, ATCC No. HTB-77), human fibrosarcoma cells (HT-1080, ATCC No.
CRL-12012), human leukemia cell line (CCRF-CEM, ATCC No. CCL-119), human breast
adenocarcinoma (MDA-MB-468, ATCC No. HTB-132), human breast adenocarcinoma cell
(MCF-7, ATCC No. HTB-22), and mouse myoblast cells (C2C12, ATCC No. CRL-1772)
were purchased from American Type Culture Collection. The cells were grown on 75 cm2
cell culture flasks with RPMI-16 medium for CCRF. DMEM for MDA-MB-468, MCF-7,
and C2C12, and EMEM for SKOV-3, HT-1080, and HEK-293, supplemented with 10% fetal
bovine serum (FBS), and 1% penicillin-streptomycin solution (10,000 units of penicillin and
10 mg of streptomycin in 0.9% NaCl) in a humidified atmosphere of 5% CO2, 95% air at 37
°C.
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4.4.

Viability assay
HEK-293 (5000 cells), SKOV-3 (5000 cells), HT-1080 (5000 cells), CCRF-CEM cells
(50,000 cells), and C2C12 (10,000 cells) were seeded in 0.1 mL per well in 96-well plates
24 h prior to the experiment. Cells were treated with 5 μM of Dox, Dox-SH, Dox-SS-Pyr, or
Dox-SS-[C(WR)4K]. Water and DMSO (0.025%) were used as negative control. Plates were
incubated for 24 or 72 h at 37 °C in a humidified atmosphere of 5% CO2. Before adding
MTT or MTS reagent, the medium of SKOV-3, HT-1080, and HEK-293 was replaced with
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fresh medium. Cell viability was then determined by measuring the fluorescence intensity
of the formazan product at 595 nm (MTT) or 490 nm (MTS) using a SpectraMax M2
microplate spectrophotometer. The percentage of cell survival was calculated as [(OD value
of cells treated with compounds) – (OD value of culture medium)]/[(OD value of control
cells) – (OD value of culture medium)] × 100.

Author Manuscript

4.4.1. Flow cytometry—HEK-293, SKOV-3, HT-1080, and CCRF-CEM cells were
taken in 6-well plates, 5 × 104 cells/well for adherent cells and 5 × 105 for CCRF-CEM
as non-adherent cells in serum-free medium and incubated overnight. The next day, Dox (5
μM), Dox-SS-Pyr (50 μM), or and Dox-SS-[C(WR)4K] (50 μM) were added to the wells.
The cells with no treatment were used as control groups. The plates were incubated for 3
h at 37 °C. After 3 h incubation at 37 °C, the medium containing the drugs treated with
HEK-293, SKOV-3, and HT-1080 cells was removed, and the cells were washed once with
Dulbecco's phosphate-buffered saline (DPBS). Then cells were detached with 0.25% trypsin/
EDTA (0.53 mM) for 5 min, neutralized with serum free fresh medium, and centrifuged at
800 rpm for 5 min to remove any artificial surface association and to detect only intracellular
uptake. For CCRF-CEM cells, the cells were collected after 3 h and centrifuged at 800 rpm
for 5 min. To wash the cells, the pellets of all cell lines were resuspended in DPBS and
centrifuged twice. Finally, the cells were resuspended in flow cytometry buffer and analyzed
by flow cytometry (FACSCalibur: BD) using TEXAS RED channel and CellQuest software
(BD FACSVerse). The data presented were based on the mean fluorescence signal for 10,000
cells collected. All assays were performed in triplicate.
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4.4.2. Detection of intracellular reactive oxygen species (ROS)—C2C12 cells
were seeded in 6-well plates in DMEM medium supplemented with 10% FBS and incubated
with 0.5% CO2 at 37 °C for 24 h prior to treatments. Cells were then incubated with 10
μM Fe2+ with or without 0.5 νM of Dox or Dox-SS-[C(WR)4K] in serum-free DMEM for
72 h. After treatments, cells were collected and stained with H2DCFDA (10 μM) in Hank's
Balanced Salt Solution (HBSS) for 30 min at 37 °C followed by flow cytometry analysis.
The mean fluorescence signal for 5000 cells is represented here as the fold of control. Each
experiment was repeated twice.
4.5.

Fluorescence microscopy

Author Manuscript

SKOV-3, HT-1080, MDA-MB-468, and MCF-7 cells were seeded on each chamber of the
μ-Slide VI0.4 plates (ibidi cat. # 80604). 1 × 104 cells in 30 μL medium were injected to
each chamber and incubated for 60 min to fix the cells. After this time, 60 μL of supplied
medium was added to each column and incubated overnight in humidified atmosphere of
95% air, 0.5% CO2 at 37 °C. The next day, the medium was removed and a solution of
120 mL of fresh supplied medium contain final concentration of 5 mM of Dox, Dox-SH,
Dox-SS-Pyr, or Dox-SS-[C(WR)4K] were added to each chamber and incubated for 1 and
24 h. Cells without treatment were considered as the control group. After each treatment
time, the medium was removed, and chambers were washed 2 times with 100 μL DPBS,
fixed with 100 μL of 4% PFA (paraformaldehyde) for 30 min and washed again with DPBS
for 2–3 times. Since Dox is fluorescent, no dye was added. To identify nucleus, the cells
were dyed with 50 μL DAPI (300 nM) for 5–10 min and washed with DPBS 2 times.
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One drop of mounting solution was added to each chamber. Plates were kept in the dark
by rolling in aluminum foil and kept at room temperature for further analysis by Keyence
Fluorescent microscope.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.

Inhibition of cells by Dox-SH (5 μM), Dox-SS-Pyr (5 μM), and Dox (5 μM) after 24 h and
72 h incubation. The results are shown as the percentage of the control cells that have no
compound (set at 100%). All the experiments were performed in triplicate (±SD).
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Fig. 2.

Inhibition of cells by Dox-SS-[C(WR)4K] (5 μM), a physical mixture of Dox, and
[C(WR)4K] (1:1 ratio based on M.W., and Dox (5 μM) after 24 h and 72 h incubation.
The results are shown as the percentage of the control cells that have no compound (set at
100%). All the experiments were performed in triplicate (±SD).
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Fig. 3.

Flow cytometry analysis (FACS) analysis of cellular uptake assays of Dox (5 μM), Dox
SS-Pyr (50 μM) and Dox-SS-[C(WR)4K] (50 μM) in HT-1080, HEK-293, SKOV-3, and
CCRF-CEM cells after 3 h of incubation (mean ± SD).
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Fig. 4.

Fluorescence microscopy images of Dox (5 μM), Dox-SH (5 μM), Dox-SS-Pyr (5 μM), and
Dox-SS-[C(WR)4K] (5 μM) uptake in HT-1080 cells after 1 h and 24 h. Cells treated with
the compound for 1 h or 24 h. Red represents the fluorescence of Dox. To identify the
nucleus, the cells were dyed with DAPI.
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Fig. 5.

Fluorescence microscopy images of Dox (5 μM), Dox-SH (5 μM), Dox-SS-Pyr (5 μM), and
Dox-SS-[C(WR)4K] (5 μM) uptake in MDA-MB-468 cells after 1 h and 24 h. Cells treated
with the compound for 1 h or 24 h. Red represents the fluorescence of Dox. To identify the
nucleus, the cells were dyed with DAPI.
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Fig. 6.

Dox-SS-[C(WR)4K] in mouse myoblast cells after 72 h incubation compared to that of Dox.
The results are shown as the folds of the control cells that have no compound (set at 100%).
All the experiments were performed in triplicate (mean ± SD). *, p < 0.05 compared to
doxorubicin.
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Fig. 7.

Flow cytometry analysis (FACS) of intracellular ROS levels using H2DCFDA staining in
C2C12 cells. Cells were treated with Fe2+ (10 μM) in the absence or presence of Dox or
Dox-SS-[C(WR)4K] (0.5 μM) for 72 h before staining with H2DCFDA (10 μM). Data is
represented as the fold of control and each experiment was repeated two times.
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Scheme 1.

Synthesis of Cyclic Peptide [C(WR)4K].
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Scheme 2.

Synthesis of Dox-SH and Dox-SS-Pyr.
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Scheme 3.

Synthesis Dox-SS-[C(WR)4K].
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